October Pharma Co.
EEGX:OCPH184.94
EGP
-5.49
(-2.88%)
ISIN
EGS380R1C018
Return %
Stock
S&P 500
1Y
71.62
14.20
3Y
326.13
81.12
5Y
543.27
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Hesham Abdul Aziz El Sayed Soliman
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Cairo Egypt
- IPO Date
- May 21, 2007
- Website
- octoberpharma.com
- Similar Companies
- Business
- October Pharma S.A.E. is an Egypt-based pharmaceutical manufacturing company engaged in the development, production, marketing, and distribution of human pharmaceuticals, veterinary medicines, cosmeceuticals, and nutritional supplements. Founded in 1987 and headquartered in 6th of October City, Egypt, the company produces a comprehensive range of pharmaceutical dosage forms, including solid oral preparations such as film-coated tablets, immediate-release tablets, and hard gelatin capsules; liquid dosage forms including oral solutions, suspensions, and syrups; semi-solid formulations such as topical creams, ointments, and gels; and rectal suppositories and vaginal ovules. October Pharma commercializes a diverse portfolio of generic and branded prescription medications and over-the-counter (OTC) healthcare products across key therapeutic areas, including cardiovascular treatments such as antihypertensive drugs, antianginal therapies, and lipid-regulating agents; central nervous system (CNS) products, including analgesics, antipyretics, anticonvulsants, and psychotropic agents; gastrointestinal medications, including proton-pump inhibitors, H2-receptor antagonists, antispasmodics, and laxatives; respiratory and anti-allergic treatments, including antihistamines, mucolytics, decongestants, and bronchodilators; anti-infective medications, including broad-spectrum antibacterial antibiotics, antiparasitics, and antifungals; musculoskeletal therapies and non-steroidal anti-inflammatory drugs (NSAIDs); metabolic and endocrine treatments, including oral antidiabetic agents; and specialized dermatological formulations and vitamin supplements. In addition to proprietary pharmaceutical manufacturing, the company provides contract manufacturing and toll manufacturing services for multinational and regional pharmaceutical partners, utilizing its industrial production complex located in the First Industrial Zone of 6th of October City. Geographically, the company serves the domestic Egyptian healthcare sector through public tenders, private hospitals, and retail pharmacy networks, while exporting finished products across the Middle East, North Africa (MENA), Sub-Saharan Africa, and Central and Eastern Europe. In recent operational developments, October Pharma has expanded its export footprint across GCC and African markets to mitigate local currency volatility and enhance foreign-currency revenue generation. The company has also executed capital modernization programs across its manufacturing facilities to align with enhanced international Good Manufacturing Practice (GMP) requirements, entered into new third-party toll manufacturing agreements, and advanced its pipeline through the registration and commercial launch of new generic therapies focused on chronic illness management in cardiology, neurology, and metabolic disorders.